Skip to main content
Evidence Snapshot

Beta-lactamase

CHEMBL1075159 SINGLE PROTEIN Acinetobacter baumannii
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:00:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1075159
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-lactamase as ChEMBL target CHEMBL1075159, mapped to UniProt Q8RLA6. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-lactamase
SINGLE PROTEIN · Acinetobacter baumannii
As of 2026-09-13
ChEMBL target ID
CHEMBL1075159
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8RLA6
Beta-lactamase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Beta-lactamase matters

As of 2026-09-13

Beta-lactamase is reviewed as Beta-lactamase (UniProt Q8RLA6); Beta-lactamase shows clinical signal disease relevance led by bacterial disease. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 33 compounds, and 94 assays, with lead potency reaching pChEMBL 6.4.

Disease context
bacterial disease

Beta-lactamase shows clinical signal disease relevance led by bacterial disease. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include DURLOBACTAM SODIUM.

Start review with bacterial disease because it currently carries clinical signal support. Linked drugs include DURLOBACTAM SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 0 approved drugs, 33 compounds, and 94 assays for this target. The dominant activity type is IC50. CHEMBL3112591 is the current potency anchor at pChEMBL 6.4.

Use CHEMBL3112591 as the tractability anchor when discussing potency (pChEMBL 6.4).

Activity source · ChEMBL 36 via Core Engine
pChEMBL 6.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Beta-lactamase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q8RLA6, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why bacterial disease is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

33
Total Compounds
94
Total Assays
0
Approved Drugs
IC50: 32.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3112591
 6.4 IC50 —
No preferred name
CHEMBL3112748
 6.3 IC50 —
No preferred name
CHEMBL3112749
 5.4 IC50 —
No preferred name
CHEMBL3112751
 5.3 IC50 —
No preferred name
CHEMBL1089781
 5.2 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:00:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1075159